AR065195A1 - Heterociclos biciclicos medicamentos que contienen estos compuestos , su utilizacion y procedimientos para su preparacion - Google Patents
Heterociclos biciclicos medicamentos que contienen estos compuestos , su utilizacion y procedimientos para su preparacionInfo
- Publication number
- AR065195A1 AR065195A1 ARP080100494A ARP080100494A AR065195A1 AR 065195 A1 AR065195 A1 AR 065195A1 AR P080100494 A ARP080100494 A AR P080100494A AR P080100494 A ARP080100494 A AR P080100494A AR 065195 A1 AR065195 A1 AR 065195A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- carbonyl
- substituted
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 28
- -1 indan-4-yl group Chemical group 0.000 abstract 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 8
- 229910052794 bromium Inorganic materials 0.000 abstract 5
- 229910052801 chlorine Inorganic materials 0.000 abstract 5
- 239000000460 chlorine Substances 0.000 abstract 5
- 229910052731 fluorine Inorganic materials 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 4
- 239000011737 fluorine Substances 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 229910052740 iodine Inorganic materials 0.000 abstract 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 2
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 abstract 1
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 abstract 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 abstract 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005002 aryl methyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Los compuestos de la presente presentan valiosas propiedades farmacologicas, en especial una accion inhibidora sobre la transduccion de senales mediada por tirosina quinasas, a su uso para el tratamiento de enfermedades, en especial de enfermedades tumorales, así como de hiperplasia benigna de prostata (BPH), de enfermedades pulmonares y de las vías respiratorias y a su produccion. Reivindicacion 1: Heterociclos bicíclicos caracterizados porque tienen la formula general (1) en los cuales Ra es un grupo fenilo, 1-feniletilo o indan-4-ilo, en los que el nucleo fenilo está sustituido en cada caso con los radicales R1 a R3, donde R1 y R2, pueden ser iguales o diferentes, en cada caso un átomo de hidrogeno, fluor, cloro, bromo o yodo, un grupo alquilo C1-4, hidroxi, alcoxi C1-4, alquenilo C2-3 o alquinilo C2-3, un grupo arilo, ariloxio, arilmetilo o arilmetoxi, un grupo heteroarilo, heteroariloxi, heteroarilmetilo o heteroarilmetoxi, un grupo metilo o metoxi sustituido con 1 a 3 átomos de fluor o un grupo ciano, nitro o amino, y R3 un átomo de hidrogeno, fluor, cloro o bromo o un grupo metilo o trifluorometilo, Rb un grupo azetidin-1-ilo, pirrolidin-1-ilo, piperidin-1-ilo, homiperidin-1-ilo, morfolin-4-ilo, homomorfolin-4- ilo, piperazin-1-ilo, 4-(alquil C1--4carbonil)-piperazin-1-ilo, 4-(alquil C1-4-sulfonil)-piperazin-1-ilo, homopiperazin-1-iIo, 4-(alquil C1-4-carbonil)-homopiperazin-1-ilo o 4-(alquil C1-4-sulfonil)-homopiperazin-1-ilo, que en cada caso puede estar mono-, di- o trisustituido con R4, en donde los sustituyentes pueden ser iguales o diferentes y R4 un átomo de fluor, cloro, bromo o yodo, un grupo alquilo C1-4, alquenilo C2-4 o alquinilo C2-4, un grupo metilo o metoxi sustituido con 1 a 3 átomos de fluor, un grupo amino, alquil C1-4-amino, di-(alquil C1-4)amino, alquil C1-4-carbonilamino, N-(alquil C1-4)-alquil C1-4-carbonilamino, alquil C1-4-sulfonilamino o N-(alquil C1-4)-alquil C1-4-sulfonilamino, un grupo amino-alquilo C1-4, alquil C1-4- amino-alquilo C1-4, di-(alquil C1-4)amino-alquilo C1-4, alquil C1-4-carbonilamino-alquilo C1-4, N-(alquil C1-4)-alquil C1-4-carbonilamino-alquilo C1-4, alquil C1-4-sulfonilamino-alquilo C1-4 o N-(alquil C1-4)-alquil C1-4-suIfonilamino-alquilo C1-4, un grupo hidroxi, alquil C1-4-oxi o alquil C1-4-carboniloxi un grupo hidroxi-alquilo C1-4, alquil C1-4-oxi-alquilo C1-4 o alquil C1-4-carboniloxi-alquilo C1-4, un grupo alquil C1-4-carbonilo, ciano, alquil C1-4-oxicarbonilo, carboxi, aminocarbonilo, alquil C1-4-aminocarbonilo, di-(alquil C1-4)amino-carbonilo, pirrolidin-1-il-carbonilo, piperidin-1-il-carbonilo, piperazin-1-il-carbonilo, 4-alquil C1-4-piperazin-1-il-carbonilo o morfolin-4-il-carbonilo, un grupo alquil C1-4-carbonil-alquilo C1-4, ciano-alquilo C1-4, alquil C1-4-oxicarbonil-alquilo C1-4, aminocarbonil-alquilo C1-4, alquil C1-4-aminocarbonil-alquil C1-4, di-(alquil C1-4)aminocarbonil-alquilo C1-4, pirrolidin-1 -il-carbonil-alquilo C1-4, piperidin-1-il-carbonil-alquilo C1-4, piperazin-1-il-carbonil-alquilo C1-4, 4-alquil C1-4-piperazin-1-il-carbonil-alquilo C1-4 o morfolin-4-il-carbonil-alquilo C1-4, un grupo alquil C1-4-sulfanilo, alquil C1-4-sulfinilo, alquil C1-4-sulfonilo, aminosulfonilo, alquil C1-4-aminosulfonilo o di-(alquil C1-4)amino-sulfonilo, un grupo alquil C14-sulfanil-alquilo C1-4, alquil C1-4-sulfinil-alquilo C1-4, alquil C1-4-sulfonil-alquilo C1-4, aminosulfonil-alquilo C1-4, alquil C1-4-aminosulfonil-alquilo C1-4 o di-(alquil C1-4)amino-sulfonil- alquilo C1-4 y en donde los heterociclos mencionados previamente en Rb pueden estar sustituidos adicionalmente con un grupo oxo, Rc un átomo de hidrogeno, un átomo de fluor, cloro, bromo o yodo, un grupo alquilo C1-4, un grupo alquilo C1-4, que está sustituido con un radical R5, en donde R5 representa un grupo hidroxi, alquil C1-3-oxi, cicloalquil C3-6-oxi, amino, alquil C1-3-amino, di-(alquil C1-3)amino, bis-(2-metoxietil)-amino, pirrolidin-1-ilo, piperidin-1-ilo, homopiperidin-1-ilo, morfolin- 4-ilo, homomorfolin-4-ilo, 2-oxa-5-aza-biciclo[2.2.1]hept-5-ilo, 3-oxa-8-aza-biciclo[3.2.1]oct-8-ilo, 8-oxa-3-aza- biciclo[3.2.1]oct-3-ilo, piperazin-1-ilo, 4-alquil C1-3-piperazin-1-ilo, homopiperazin-1-ilo o alquil C1-3-homopiperazin-1-ilo o un grupo formilamino, alquil C1-4-carbonilamino, alquil C1-3-oxi-alquil C1-3-carbonilamino, alquil C1-4-oxicarbonilamino, aminocarbonilamino, alquil C1-3-aminocarbonilamino, di-(alquil C1-3)aminocarbonilamino, pirrolidin-1-ilcarbonilamino, piperidin-1- ilcarbonilamino, piperazin-1-ilcarbonilamino, 4-alquil C1-3-piperazin-1-ilcarbonilamino, morfolin-4-ilcarbonilamino o un grupo alquil C1-4-sulfonilamino, un grupo hidroxi, un grupo alquil C1-4-oxi, un grupo metoxi o etiloxi sustituido con 1 a 3 átomos de fluor, un grupo alquil C2-4-oxi, que está sustituido con el radical R5, en donde R5 se define como se menciono con anterioridad, un grupo cicloalquil C3-7-oxi o cicloalquil C3-7-alquil C1-4-oxi, un grupo tetrahidrofuran-3-iloxi, tetrahidropiran-3-iloxi o tetrahidropiran-4-iloxi, un grupo tetrahidrofuranil-alquil C1-4-oxi o tetrahidropiranil-alquil C1-4-oxi, un grupo alcoxi C1-4, que está sustituido con un grupo pirrolidinilo, piperidinilo o homopiperidinilo sustituido con el radical R6 sustituido en posicion 1, en donde R6 representa un átomo de hidrogeno o un grupo alquilo C1-3, o un grupo alcoxi C1-4, que está sustituido con un grupo morfolinilo sustituido en posicion 4 con el radical R6, en donde R6 se define como se menciono con anterioridad, y en donde los grupos pirrolidinilo, piperidinilo, piperazinilo y morfolinilo mencionados previamente en la definicion del radical Rc en cada caso pueden estar sustituidos con uno o dos grupos alquilo C1-3, y en donde por grupos arilo mencionados en la definicion de los radicales previamente citados en cada caso se debe entender un grupo fenilo, que está mono- o disustituido con R7, en donde los sustituyentes pueden ser iguales o diferentes y R7 representa un átomo de hidrogeno, un átomo de fluor, cloro, bromo o yodo o un grupo alquilo C1-3, hidroxi, alquil C1-3-oxi, difluorometilo, trifluorometilo, difluorometoxi, trifluorometoxi o ciano, y por grupo heteroarilo mencionados en la definicion de los radicales previamente citados se entiende un grupo piridilo, piridazinilo, pirimidinilo o pirazinilo, en donde los grupos heteroarilo previamente citados en cada caso están mono- o disustituidos con el radical R7, en donde los sustituyentes pueden ser iguales o diferentes y R7 se define como se menciono con anterioridad, y siempre y cuando no se haya mencionado otra cosa, los grupos alquilo previamente mencionados pueden ser de cadena lineal o ramificada, sus tautomeros, sus estereoisomeros, sus mezclas y sus sales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07101785A EP1956010A1 (de) | 2007-02-06 | 2007-02-06 | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel,deren Verwendung und Verfahren zu ihrer Herstellung |
EP07118700 | 2007-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065195A1 true AR065195A1 (es) | 2009-05-20 |
Family
ID=39247377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100494A AR065195A1 (es) | 2007-02-06 | 2008-02-05 | Heterociclos biciclicos medicamentos que contienen estos compuestos , su utilizacion y procedimientos para su preparacion |
Country Status (18)
Country | Link |
---|---|
US (1) | US7998949B2 (es) |
EP (1) | EP2118075A1 (es) |
JP (1) | JP5377332B2 (es) |
KR (1) | KR20090116782A (es) |
AR (1) | AR065195A1 (es) |
AU (1) | AU2008212999A1 (es) |
BR (1) | BRPI0807234A2 (es) |
CA (1) | CA2677336A1 (es) |
CL (1) | CL2008000356A1 (es) |
CO (1) | CO6210816A2 (es) |
EA (1) | EA200901041A1 (es) |
EC (1) | ECSP099562A (es) |
IL (1) | IL199923A0 (es) |
MA (1) | MA31171B1 (es) |
MX (1) | MX2009007610A (es) |
TN (1) | TN2009000332A1 (es) |
TW (1) | TW200846330A (es) |
WO (1) | WO2008095847A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
ME01461B (me) | 2008-02-07 | 2014-04-20 | Boehringer Ingelheim Int | Spirociklični heterocikli, ljekovi koji sadrže navedeno jedinjenje, njihova primjena i postupak za njihovu proizvodnju. |
JP5611207B2 (ja) * | 2008-08-08 | 2014-10-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式複素環の立体選択的調製方法 |
EP2313397B1 (de) * | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US8629153B2 (en) | 2008-09-03 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Use of quinazoline derivatives for the treatment of viral diseases |
EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
KR20140096571A (ko) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3985749A (en) | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
GB2160201B (en) | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
US4845629A (en) | 1985-07-18 | 1989-07-04 | General De Investigacion Y Desarrollo S.A. | Airport surveillance systems |
KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
US4921863A (en) | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
GB8910722D0 (en) | 1989-05-10 | 1989-06-28 | Smithkline Beckman Intercredit | Compounds |
US5252586A (en) | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
DE4105503A1 (de) | 1991-02-19 | 1992-08-20 | Jenapharm Gmbh | Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
KR100322325B1 (ko) | 1993-05-26 | 2002-06-20 | 헤르빅 폰 모르체 | 신규한1-페닐알카논5-ht4수용체리간드 |
US5395846A (en) | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (es) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
US5642285A (en) | 1995-01-31 | 1997-06-24 | Trimble Navigation Limited | Outdoor movie camera GPS-position and time code data-logging for special effects production |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
EP0824525B1 (en) | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JPH11512708A (ja) | 1995-09-11 | 1999-11-02 | オステオアルスリィティス サイエンシズ,インコーポレイテッド | 変形性関節炎を治療するためのプロテインチロシンキナーゼインヒビター |
WO1997018813A1 (en) | 1995-11-22 | 1997-05-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
BR9702049B1 (pt) | 1996-01-31 | 2010-08-10 | sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas. | |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US5938706A (en) | 1996-07-08 | 1999-08-17 | Feldman; Yasha I. | Multi element security system |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
US6004967A (en) | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
DE69740095D1 (de) | 1996-11-05 | 2011-02-17 | Childrens Medical Center | Thalidomide und Dexamethason für die Behandlung von Tumors |
ATE554750T1 (de) | 1997-03-05 | 2012-05-15 | Sugen Inc | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
ATE260931T1 (de) | 1997-06-30 | 2004-03-15 | Glaxo Group Ltd | Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
KR20010031813A (ko) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도 |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
AU4317399A (en) | 1998-05-28 | 1999-12-13 | Parker Hughes Institute | Quinazolines for treating brain tumor |
AU4851599A (en) | 1998-06-30 | 2000-01-17 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
AR020114A1 (es) | 1998-07-30 | 2002-04-10 | America Home Products Corp | Proceso para la preparacion de derivados de quinazolina sustituida y compuestos para su exclusivo uso en dicho proceso |
US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
WO2000009481A1 (fr) | 1998-08-11 | 2000-02-24 | Takeda Chemical Industries, Ltd. | Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides |
US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
BR9912672A (pt) | 1998-08-18 | 2002-06-11 | Univ California | Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
WO2000010981A1 (en) | 1998-08-21 | 2000-03-02 | Parker Hughes Institute | Quinazoline derivatives |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
CN1144786C (zh) | 1998-09-29 | 2004-04-07 | 美国氰胺公司 | 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉 |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
IL142257A0 (en) | 1998-10-01 | 2002-03-10 | Astrazeneca Ab | Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases |
TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
CZ306810B6 (cs) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
ID29800A (id) | 1999-02-27 | 2001-10-11 | Boehringer Ingelheim Pharma | Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911510A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
JP2002539262A (ja) | 1999-03-19 | 2002-11-19 | パーカー ヒューズ インスティテュート | キナゾリン化合物製剤および治療におけるその使用 |
CA2373073A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6126917A (en) | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
YU90901A (sh) | 1999-06-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg. | Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje |
WO2001004102A1 (en) | 1999-07-07 | 2001-01-18 | Astrazeneca Uk Limited | Quinazoline derivatives |
GB9917408D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
IL147913A0 (en) | 1999-08-12 | 2002-08-14 | American Cyanamid Co | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
AU763242B2 (en) | 1999-09-21 | 2003-07-17 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
RU2002110461A (ru) | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
SV2002000205A (es) | 1999-11-01 | 2002-06-07 | Lilly Co Eli | Compuestos farmaceuticos ref. x-01095 |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
JP2003518023A (ja) | 1999-11-30 | 2003-06-03 | パーカー ヒューズ インスティテュート | トロンビン誘導血小板凝集の阻害剤 |
DE60112268T2 (de) | 2000-03-06 | 2006-05-24 | Astrazeneca Ab | Verwendung von quinazolinderivate als inhibitoren der angiogenese |
US20060063752A1 (en) | 2000-03-14 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
JP4970689B2 (ja) | 2000-04-07 | 2012-07-11 | アストラゼネカ アクチボラグ | キナゾリン化合物 |
MXPA02009855A (es) | 2000-04-08 | 2003-03-27 | Boehringer Ingelheim Pharma | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion. |
US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
WO2001087293A1 (fr) | 2000-05-19 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Inhibiteurs de la ?-secretase |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
CA2413424C (en) | 2000-06-22 | 2007-10-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
CZ2003486A3 (cs) | 2000-08-21 | 2003-05-14 | Astrazeneca Ab | Chinazolinové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6653305B2 (en) | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US20020082270A1 (en) | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042061A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10042062A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung |
DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
AU2002218192A1 (en) | 2000-09-21 | 2002-04-02 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
JP2004511479A (ja) | 2000-10-13 | 2004-04-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
MXPA03009130A (es) | 2000-10-20 | 2004-02-26 | Biocryst Pharm Inc | Compuestos de biarilo que funcionan como inhibidores de proteasa serina. |
WO2002034744A1 (en) | 2000-10-25 | 2002-05-02 | Astrazeneca Ab | Quinazoline derivatives |
US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
ATE369894T1 (de) | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
WO2002062767A1 (fr) | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux derives de quinazoline |
NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
DE60237145D1 (de) | 2001-02-21 | 2010-09-09 | Mitsubishi Tanabe Pharma Corp | Chinazolinderivate |
PL364625A1 (en) | 2001-02-23 | 2004-12-13 | Merck & Co, Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
AR035791A1 (es) | 2001-03-23 | 2004-07-14 | Bayer Corp | Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto |
JP4615755B2 (ja) | 2001-04-04 | 2011-01-19 | セイコーインスツル株式会社 | 半導体装置の製造方法 |
WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
AR033765A1 (es) | 2001-05-22 | 2004-01-07 | Syngenta Participations Ag | Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos. |
WO2002094790A1 (fr) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
EP1444210B1 (en) | 2001-11-03 | 2009-02-18 | AstraZeneca AB | Qunazoline derivatives as antitumor agents |
GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
GB0128109D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
CN1602195A (zh) | 2001-12-12 | 2005-03-30 | 辉瑞产品公司 | 用于治疗异常细胞生长的喹唑啉衍生物 |
DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EA200701302A1 (ru) * | 2002-03-30 | 2007-12-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы |
US20040044014A1 (en) | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
KR20050122199A (ko) | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도 |
GB0309009D0 (en) | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
DE10326186A1 (de) | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US20050059661A1 (en) | 2003-07-28 | 2005-03-17 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
CA2533345A1 (en) | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0321648D0 (en) | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
CN1882573A (zh) | 2003-09-16 | 2006-12-20 | 阿斯利康(瑞典)有限公司 | 作为酪氨酸激酶抑制剂的喹唑啉衍生物 |
US20070037837A1 (en) | 2003-09-19 | 2007-02-15 | Hennequin Laurent Francois A | Quinazoline derivatives |
SI1667992T1 (sl) | 2003-09-19 | 2007-06-30 | Astrazeneca Ab | Kinazolinski derivati |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06003341A (es) | 2003-09-25 | 2006-06-08 | Astrazeneca Ab | Derivados de quinazolina. |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
DE10350717A1 (de) | 2003-10-30 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
EP1817310A1 (en) | 2004-09-17 | 2007-08-15 | OSI Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-kit proto-oncogene inhibitors |
EP1966189A1 (de) | 2005-12-12 | 2008-09-10 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
-
2008
- 2008-01-30 AU AU2008212999A patent/AU2008212999A1/en not_active Abandoned
- 2008-01-30 BR BRPI0807234-5A patent/BRPI0807234A2/pt not_active IP Right Cessation
- 2008-01-30 EA EA200901041A patent/EA200901041A1/ru unknown
- 2008-01-30 MX MX2009007610A patent/MX2009007610A/es not_active Application Discontinuation
- 2008-01-30 KR KR1020097018469A patent/KR20090116782A/ko not_active Application Discontinuation
- 2008-01-30 WO PCT/EP2008/051141 patent/WO2008095847A1/de active Application Filing
- 2008-01-30 US US12/525,742 patent/US7998949B2/en active Active
- 2008-01-30 JP JP2009548658A patent/JP5377332B2/ja not_active Expired - Fee Related
- 2008-01-30 CA CA002677336A patent/CA2677336A1/en not_active Abandoned
- 2008-01-30 EP EP08708456A patent/EP2118075A1/de not_active Ceased
- 2008-02-05 CL CL2008000356A patent/CL2008000356A1/es unknown
- 2008-02-05 AR ARP080100494A patent/AR065195A1/es unknown
- 2008-02-05 TW TW097104708A patent/TW200846330A/zh unknown
-
2009
- 2009-07-16 IL IL199923A patent/IL199923A0/en unknown
- 2009-08-05 EC EC2009009562A patent/ECSP099562A/es unknown
- 2009-08-05 TN TNP2009000332A patent/TN2009000332A1/fr unknown
- 2009-08-05 CO CO09081877A patent/CO6210816A2/es not_active Application Discontinuation
- 2009-08-06 MA MA32150A patent/MA31171B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010518045A (ja) | 2010-05-27 |
EP2118075A1 (de) | 2009-11-18 |
AU2008212999A1 (en) | 2008-08-14 |
US7998949B2 (en) | 2011-08-16 |
US20100022505A1 (en) | 2010-01-28 |
EA200901041A1 (ru) | 2010-02-26 |
KR20090116782A (ko) | 2009-11-11 |
TW200846330A (en) | 2008-12-01 |
JP5377332B2 (ja) | 2013-12-25 |
CA2677336A1 (en) | 2008-08-14 |
CO6210816A2 (es) | 2010-10-20 |
CL2008000356A1 (es) | 2009-03-27 |
IL199923A0 (en) | 2010-04-15 |
WO2008095847A1 (de) | 2008-08-14 |
BRPI0807234A2 (pt) | 2014-06-03 |
MA31171B1 (fr) | 2010-02-01 |
TN2009000332A1 (fr) | 2010-12-31 |
MX2009007610A (es) | 2009-07-24 |
ECSP099562A (es) | 2009-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065195A1 (es) | Heterociclos biciclicos medicamentos que contienen estos compuestos , su utilizacion y procedimientos para su preparacion | |
MX2020003552A (es) | Formas cristalinas. | |
PE20190918A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
AR090230A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
AR095018A1 (es) | Procesos e intermedios para hacer un inhibidor de jak | |
CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
EA201890650A1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
AR039187A1 (es) | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion | |
IN2014CN04310A (es) | ||
AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
PH12015501567A1 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
AR090994A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
AR073483A1 (es) | Uso de derivados de quinazolina para el tratamiento de enfermedades viricas | |
EA201300288A1 (ru) | Имидазо[4,5-c]хинолины в качестве ингибиторов днк-пк | |
CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
AR097024A1 (es) | Derivados sustituidos de quinazolin-4-ona | |
AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
BR112014022000A8 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
AR070595A1 (es) | Heterociclos espirociclicos, su uso para tratar enfermedades, formulacion farmaceutica y combinaciones medicamentosas en base al compuesto | |
AR115015A1 (es) | Derivados de azaespiro piperazina | |
AR097756A1 (es) | Derivados de fenilalanina sustituidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |